The elevated MCL-1 found in many tumour types63 is implicated in therapy resistance, including of some breast and lung cancers,102, 103 and many studies68, 104, 105 show that MCL-1 mediates resistance to navitoclax and venetoclax, as their complementary targets suggest (Figures 2b and c). Here, MCL1 is linked to lung carcinoma.